Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

Journal of Perinatology volume 28, pages 511–517 (2008)Cite this article

Abstract

Objective:

The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.

Study Design:

Prospective observational registry enrolling those who received ⩾1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.

Result:

Of 19 548 subjects enrolled, 40% were born before 32 weeks’, 48% between 32 and 35 weeks’ and 12% after 35 weeks’ gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.

Conclusion:

Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

Article 08 April 2021

Antoni Torres, Catia Cilloniz, … Tom van der Poll

References

  1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ . Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 1999; 282: 1440–1446.

    Article  CAS  Google Scholar 

  2. Leader S, Kohlhase K . Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997–2000. J Pediatr 2003; 143: S127–S132.

    Article  Google Scholar 

  3. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179–186.

    Article  Google Scholar 

  4. Boyce TG, Mellen BG, Mitchel Jr EF, Wright PF, Griffin MR . Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137: 865–870.

    Article  CAS  Google Scholar 

  5. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA . Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397–400.

    Article  CAS  Google Scholar 

  6. Navas L, Wang E, de Carvalho V, Robinson J . Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992; 121: 348–354.

    Article  CAS  Google Scholar 

  7. Figueras-Aloy J, Carbonell-Estrany X, Quero J . Case–control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J 2004; 23: 815–820.

    Article  Google Scholar 

  8. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23: 806–814.

    Article  Google Scholar 

  9. Simoes EA . Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003; 143: S118–S126.

    Article  Google Scholar 

  10. Meissner HC . Commentary: the unresolved issue of risk factors for hospitalization of infants with respiratory syncytial virus infection born after 32–35 weeks gestation. Pediatr Infect Dis J 2004; 23: 821–823.

    Article  Google Scholar 

  11. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J, et al., IRIS Study Group. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. Pediatr Infect Dis J 2000; 19: 592–597.

    Article  CAS  Google Scholar 

  12. Wang EE, Law BJ, Stephens D . Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995; 126: 212–219.

    Article  CAS  Google Scholar 

  13. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531–537.

    Article  Google Scholar 

  14. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top Jr FH et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532–540.

    Article  CAS  Google Scholar 

  15. American Academy of Pediatrics, Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211–1216.

    Article  Google Scholar 

  16. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1442–1446.

    Article  Google Scholar 

  17. American Academy of Pediatrics. Respiratory syncytial virus In: Pickering LK, Baker CJ, Long SS, McMillan JA (eds). Red Book: 2006 Report of the Committee on Infectious Diseases,27th edn. American Academy of Pediatrics: Elk Grove Village, IL, 2006,pp 506–566.

  18. Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003; 35: 484–489.

    Article  Google Scholar 

  19. Romero JR . Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 2003; 22: S46–S54.

    PubMed  Google Scholar 

  20. Cohen SA, Zanni R, Cohen A, Harrington M, VanVeldhuisen P, Boron ML . Palivizumab use in subjects with congenital heart disease: results from the 2000–2004 Palivizumab Outcomes Registry. Pediatr Cardiol 2007; 29: 382–387.

    Article  Google Scholar 

  21. Centers for Disease Control and Prevention. Respiratory syncytial virus activity—United States, 2000–2001 season. MMWR Morb Mortal Wkly Rep 2002; 51: 26–28.

    Google Scholar 

  22. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ . Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003; 22: 483–490.

    PubMed  Google Scholar 

  23. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ . Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 2001; 183: 16–22.

    Article  CAS  Google Scholar 

  24. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML . Births: final data for 2003. Natl Vital Stat Rep 2005; 54: 1–116.

    Google Scholar 

  25. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J . Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003; 22: 823–827.

    Article  Google Scholar 

  26. Cohen AH, Sorrentino M, Powers T . Effectiveness of palivizumab for preventing serious RSV disease. J Respir Dis 2000; 2 (Suppl): S30–S32.

    Google Scholar 

  27. Sorrentino M, Powers T . Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000; 19: 1068–1071.

    Article  CAS  Google Scholar 

  28. Mullins JA, Lamonte AC, Bresee JS, Anderson LJ . Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J 2003; 22: 857–862.

    Article  Google Scholar 

  29. Terletskaia-Ladwig E, Enders G, Schalasta G, Enders M . Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study. BMC Infect Dis 2005; 5: 20.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Lisa M Klumpp and Marissa Buttaro of Scientific Connexions for their assistance in drafting the paper. Support for this study was provided by MedImmune.

Author information

Authors and Affiliations

  1. Division of General Pediatrics, Schneider Children's Hospital, New Hyde Park, NY, USA

    M Frogel & C Nerwen

  2. Medical and Scientific Affairs, MedImmune, Gaithersburg, MD, USA

    A Cohen & M Boron

  3. The Synagis Outcomes Registry Coordinating Center, The EMMES Corporation, Rockville, MD, USA

    P VanVeldhuisen & M Harrington

Authors
  1. M Frogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Nerwen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P VanVeldhuisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Boron
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Palivizumab Outcomes Registry Group

Corresponding author

Correspondence to M Frogel.

Additional information

Financial disclosures

Dr Frogel has served as a consultant to MedImmune and participated in IRB-approved research supported by MedImmune.

Dr Nerwen participated in IRB-approved research, the Palivizumab Outcomes Registry, supported by MedImmune.

Dr Boron is an employee of MedImmune.

Dr Cohen was an employee of MedImmune during the drafting stage of this paper. He is now with Jazz Pharmaceuticals, Palo Alto, CA, USA.

Dr VanVeldhuisen and Ms Harrington are employees of The EMMES Corporation, the contract research organization that undertook data collection and analysis for the Palivizumab Outcomes Registry.

Supplementary Information accompanies the paper on the Journal of Perinatology website (http://www.nature.com/jp)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frogel, M., Nerwen, C., Cohen, A. et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 28, 511–517 (2008). https://doi.org/10.1038/jp.2008.28

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jp.2008.28

Keywords

This article is cited by

Search

Advanced search

Quick links